CollPlant Biotechnologies Ltd. (CLGN) has a negative trailing P/E of -0.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -253.85%, forward earnings yield 55.56%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.5 | -0.09 | 13.50 | 238.60 | - |
| 2017 | -4.1 | 0.11 | 9.17 | 49.95 | - |
| 2018 | -2.9 | 0.08 | 3.87 | 3.85 | - |
| 2019 | -2.5 | -0.02 | 6.95 | 12.26 | - |
| 2020 | -12.8 | 0.18 | 16.57 | 12.09 | - |
| 2021 | 688.2 | -6.56 | 3.61 | 10.43 | - |
| 2022 | -5.4 | 0.00 | 2.85 | 308.12 | - |
| 2023 | -10.4 | 0.18 | 2.57 | 6.64 | - |
| 2024 | -2.5 | -0.02 | 3.06 | 80.07 | - |
| 2025 | -1.5 | 0.04 | 2.81 | 7.21 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.60 | $75.91K | $-7.24M | -9537% |
| 2017 | $-2.27 | $479.92K | $-6.05M | -1260.8% |
| 2018 | $-1.43 | $4.79M | $-6.25M | -130.5% |
| 2019 | $-2.95 | $2.32M | $-14.7M | -634% |
| 2020 | $-0.84 | $6.14M | $-5.81M | -94.6% |
| 2021 | $0.03 | $15.64M | $409K | 2.6% |
| 2022 | $-1.52 | $299K | $-16.75M | -5603% |
| 2023 | $-0.62 | $10.96M | $-7.02M | -64% |
| 2024 | $-1.45 | $515K | $-16.61M | -3225% |
| 2025 | $-0.94 | $2.37M | $-11.49M | -484.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.59 | $-0.98 – $-0.20 | $2M | $980.86K – $3.02M | 1 |
| 2027 | $-0.18 | $-6.48 – $6.12 | $2.5M | $532.2K – $4.47M | 2 |
| 2028 | $0.19 | $0.10 – $0.28 | $30M | $14.71M – $45.29M | 2 |
| 2029 | $0.38 | $0.13 – $0.63 | $46.7M | $22.9M – $70.5M | 1 |
| 2030 | $0.61 | $0.21 – $1.01 | $68.8M | $33.74M – $103.86M | 1 |
